Nova Eye Medical Acquires Glaucoma Treatment Patents from Dallas Company

Australian company Nova Eye Medical announced Aug. 26 that it had completed an acquisition of a patent portfolio related to ab interno trabeculotomy from Innovative Glaucoma Solutions, a surgeon-owned company in Dallas. Nova Eye, which maintains a US base in Fremont, California, paid US $2 million up front and 1.7 million in Nova Eye shares for the acquisition. Tom Spurling, managing director …

Artificial intelligence may accurately identify glaucoma medication bottles

Artificial intelligence has demonstrated the ability to differentiate bottles of ophthalmic medications and could feasibly function on a smartphone platform, according to a study published in Ophthalmology Glaucoma. Researchers pretrained seven convolutional neural network (CNN) models to classify five common ophthalmic medications using a set of 2,250 images captured by mobile phones. The two top-performing networks were included in separate iOS …

Glaucoma Devices’ Expanding Role to Drive Double-Digit Market Growth

Glaucoma surgical devices will see increased use in all stages of disease and in stand-alone glaucoma procedures over the next 5 years, as companies commercialize more devices designed to meet these needs, according to a Market Scope report. Market Scope expects the glaucoma surgical device market to grow from nearly $800 million in 2021 to $1.7 billion in 2026, at …

Visus Therapeutics Expands Ophthalmic Drug Portfolio With Investigational Therapies for Glaucoma and AMD

Visus Therapeutics announced it has entered into a worldwide exclusive licensing agreement with Cella Therapeutics to develop an array of investigational ophthalmic therapies to treat glaucoma and age-related macular degeneration (AMD). The company also announced a worldwide exclusive licensing agreement with DelSiTech, a provider of biodegradable, silica-based, controlled-release materials, to develop novel drug delivery technology that can help optimize the clinical …

Omni surgical system reduces IOP, medication use

The Omni surgical system reduced IOP through 3 months in patients with open-angle glaucoma, according to research presented at the American Society of Cataract and Refractive Surgery meeting. Brian Flowers, MD, presented 3-month interim data from the ORION study exploring the efficacy and safety of the Omni surgical system (Sight Sciences) in pseudophakic eyes with mild to moderate open-angle glaucoma. Patients …